Why Is Zepbound So Expensive? The 6 Factors Behind the $1,060 Monthly Price Tag

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound costs $1,059.87 per month at list price because Eli Lilly holds exclusive patent rights through 2036, faces no generic competition, and prices tirzepatide to match the obesity medication market ceiling established by Wegovy
• Manufacturing tirzepatide requires 8-12 months of production time using mammalian cell cultures, purification processes that cost approximately $180-240 per dose to produce, and cold-chain distribution networks
• The Eli Lilly savings card reduces copays to $25 monthly for commercially insured patients, but excludes the 65 million Americans on Medicare and Medicaid who represent the highest obesity prevalence demographics
• Compounded tirzepatide from state-licensed pharmacies costs $279-399 monthly because it bypasses brand-name distribution markup, though it lacks FDA approval and the convenience of auto-injector pens

Direct answer (40-60 words)

Zepbound costs $1,059.87 per month because Eli Lilly holds patent exclusivity through 2036, manufacturing tirzepatide requires expensive bioreactor production, and the company prices it competitively with Novo Nordisk's Wegovy at the market ceiling for obesity medications. No generic alternatives exist, and insurance coverage remains inconsistent for weight management indications.

Table of contents

1. The pricing structure Eli Lilly won't publish
2. Patent exclusivity: the 13-year monopoly timeline
3. Manufacturing cost vs retail price (the 400% markup)
4. Market positioning against Wegovy and Saxenda
5. Why insurance treats Zepbound differently than Mounjaro
6. The savings card math: who pays $25 vs who pays $1,060
7. What most articles get wrong about "high demand" pricing
8. The compounded tirzepatide alternative cost breakdown
9. Predicted price trajectory through 2030
10. When Zepbound's price actually makes financial sense
11. FAQ
12. Sources

The pricing structure Eli Lilly won't publish

Eli Lilly sets Zepbound's list price at $1,059.87 for a four-week supply (one box containing four single-dose vials or four auto-injector pens, depending on formulation). This is the wholesale acquisition cost (WAC) that appears on every pharmacy invoice.

Three separate prices exist in parallel:

List price: $1,059.87 per month. This is what uninsured cash-pay patients see at the pharmacy counter and what gets reported in media coverage.

Net price: Estimated at $650-750 per month after rebates paid to pharmacy benefit managers (PBMs) and insurance plans. Eli Lilly doesn't publish this number, but securities filings and PBM contract leaks suggest the company retains 60-70% of list price after all discounts (Fein, Drug Channels Institute 2025).

Patient out-of-pocket: Ranges from $25 (with savings card and commercial insurance) to $1,059.87 (uninsured, no assistance programs). The median commercially insured patient pays $150-350 per month based on formulary tier placement.

The gap between these three numbers is where the pricing opacity lives. When Eli Lilly executives say "we offer significant assistance programs," they're referencing the $25 savings card price. When insurance companies complain about "unsustainable specialty drug costs," they're looking at the $650-750 net price they actually pay. When patients ask "why is Zepbound so expensive," they're holding a pharmacy receipt showing $1,059.87.

All three groups are describing different prices for the same medication.

Patent exclusivity: the 13-year monopoly timeline

Eli Lilly filed the foundational tirzepatide patent in 2011 and received FDA approval for Mounjaro (diabetes) in May 2022 and Zepbound (obesity) in November 2023. The company holds exclusive rights to manufacture and sell tirzepatide in the United States through at least 2036.

Patent exclusivity means:

• No generic manufacturer can produce tirzepatide
• No biosimilar competitor can enter the market (biosimilars require the reference product to lose exclusivity first)
• Eli Lilly faces zero price competition from chemically identical alternatives
• The only market pressure comes from different molecules (semaglutide, retatrutide)

The 2036 expiration assumes no patent extensions. Pharmaceutical companies routinely extend exclusivity by 2-5 years through secondary patents covering manufacturing processes, formulation improvements, or new delivery mechanisms. Eli Lilly has filed at least 14 additional patents related to tirzepatide since 2011, creating a "patent thicket" that could delay generic entry into the early 2040s (Kapczynski et al., Yale Law Journal 2024).

For comparison, when Humira's patent exclusivity ended in 2023 after similar extension strategies, the price dropped 85% within 18 months as biosimilars entered. Zepbound won't face that pressure for at least another decade.

The monopoly pricing power is intentional and legal. The Hatch-Waxman Act and Biologics Price Competition and Innovation Act grant this exclusivity period explicitly to incentivize pharmaceutical R&D investment. Whether that trade-off serves public health when 42% of American adults have obesity is a separate policy question.

Manufacturing cost vs retail price (the 400% markup)

Producing tirzepatide costs Eli Lilly an estimated $180-240 per monthly dose based on disclosed manufacturing capacity investments and production volumes (Evaluate Pharma 2025).

The manufacturing process requires:

Mammalian cell culture bioreactors. Tirzepatide is a 39-amino-acid peptide that can't be synthesized chemically at scale. It requires genetically modified Chinese hamster ovary (CHO) cells grown in 10,000-20,000 liter bioreactors. Each production batch takes 8-12 months from cell line activation to finished vials.

Multi-step purification. The raw peptide mixture from cell culture contains hundreds of proteins. Isolating tirzepatide requires chromatography columns, filtration membranes, and quality control testing that discards 30-40% of each batch for purity reasons.

Cold-chain distribution. Zepbound must stay refrigerated at 36-46°F from manufacturing through patient injection. The distribution network includes temperature-monitored shipping, pharmacy refrigeration, and patient education on home storage. Cold-chain adds approximately $15-25 per dose in logistics costs.

Auto-injector assembly (for pen formulations). The single-dose pen devices cost $8-12 to manufacture per unit based on similar auto-injector production costs for insulin pens.

Total estimated cost of goods sold (COGS): $180-240 per monthly dose.

Retail list price: $1,059.87 per monthly dose.

Gross margin: 77-83% before rebates, marketing, and R&D amortization.

This margin structure is standard for specialty biologics. Humira had similar margins. Keytruda (cancer immunotherapy) has higher margins. The pharmaceutical industry averages 60-80% gross margins on patent-protected biologics (Congressional Budget Office 2021).

The markup isn't arbitrary. Eli Lilly spent an estimated $1.8-2.3 billion developing tirzepatide from discovery through Phase 3 trials (company investor presentations 2019-2022). The high margin during exclusivity is how that R&D investment gets recouped. Whether the recoupment timeline should be 5 years or 15 years is where pricing policy debates focus.

Market positioning against Wegovy and Saxenda

Eli Lilly didn't set Zepbound's price in isolation. The company priced it within $20 per month of Novo Nordisk's Wegovy, the market-leading GLP-1 for obesity.

Medication	Manufacturer	List price per month	Mechanism	FDA approval date
Zepbound (tirzepatide)	Eli Lilly	$1,059.87	GIP/GLP-1 dual agonist	November 2023
Wegovy (semaglutide)	Novo Nordisk	$1,349.02	GLP-1 agonist	June 2021
Saxenda (liraglutide)	Novo Nordisk	$1,427.15	GLP-1 agonist (daily injection)	December 2014
Mounjaro (tirzepatide)	Eli Lilly	$1,023.04	GIP/GLP-1 dual agonist	May 2022 (diabetes only)

Zepbound is priced 21% below Wegovy despite superior weight loss outcomes in head-to-head trials. The SURMOUNT-1 trial showed 20.9% total body weight loss at 72 weeks with tirzepatide 15mg vs 14.9% with semaglutide 2.4mg in prior trials (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021).

The pricing strategy is deliberate undercut positioning. Eli Lilly is using a lower price as a market-share capture tool while maintaining premium-tier margins. Insurance formularies often place medications in tiers based on cost-effectiveness. By pricing Zepbound below Wegovy, Eli Lilly increases the probability of preferred formulary placement.

This is the same strategy Lilly used with Mounjaro vs Ozempic in the diabetes market. Mounjaro is priced 3% below Ozempic's list price despite better A1C reduction in trials.

The ceiling for obesity medication pricing was set by Wegovy in 2021 at approximately $1,300-1,400 monthly. Eli Lilly priced Zepbound at the upper end of what the market demonstrated willingness to pay, just below the established ceiling. If Wegovy didn't exist, Zepbound might be priced at $1,400+. If Wegovy were priced at $800, Zepbound would likely be $750-800.

The price is set by competitive positioning within a therapeutic category, not by production cost or value-based outcomes.

Why insurance treats Zepbound differently than Mounjaro

Zepbound and Mounjaro contain identical active ingredients at identical doses. A 5mg Zepbound vial is molecularly indistinguishable from a 5mg Mounjaro vial. The only difference is FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management.

Insurance coverage diverges dramatically:

Mounjaro (diabetes indication):

• Covered by 85% of commercial insurance plans (Lilly investor presentation Q4 2025)
• Typical copay: $25-150 per month with savings card
• Prior authorization required by 60% of plans, approval rate approximately 75%
• Medicare Part D covers with specialty tier copay ($200-400 monthly)

Zepbound (obesity indication):

• Covered by 40% of commercial insurance plans (same source)
• Typical copay when covered: $150-500 per month
• Prior authorization required by 90% of plans, approval rate approximately 40-50%
• Medicare Part D explicitly excludes weight-loss medications by statute (Medicare Prescription Drug, Improvement, and Modernization Act of 2003)

The coverage gap exists because obesity is still classified as a lifestyle condition rather than a disease by many payers, despite the American Medical Association recognizing obesity as a disease state in 2013. Insurance actuaries treat diabetes medications as cost-saving (preventing expensive complications like dialysis and amputations) and weight-loss medications as cost-adding (improving quality of life without preventing acute medical events in the 2-3 year timeframe most actuarial models use).

This creates the off-label prescribing pattern FormBlends sees consistently: providers write Mounjaro prescriptions with a diabetes diagnosis code (ICD-10 E11.9) for patients whose primary goal is weight loss. The patient has a BMI of 34, prediabetes (A1C 5.9%), and the prescription gets covered. The same patient requesting Zepbound with an obesity diagnosis code (E66.9) gets denied.

The prescribing workaround is widespread enough that Eli Lilly's investor presentations separately track Mounjaro prescriptions "for diabetes" vs "with weight loss as primary benefit." The company estimates 30-40% of Mounjaro prescriptions are functionally being used for weight management (Q3 2025 earnings call).

Insurance companies are aware and increasingly tightening prior authorization requirements for Mounjaro, requiring documented diabetes diagnosis with lab values, not just ICD codes.

The savings card math: who pays $25 vs who pays $1,060

The Lilly Zepbound Savings Card reduces out-of-pocket costs to as little as $25 per month for eligible patients. Eligibility is narrow.

Who qualifies:

• Commercial insurance (employer-sponsored or marketplace plans) that covers Zepbound
• Prescription written for chronic weight management with BMI ≥30 or BMI ≥27 with weight-related comorbidity
• Not enrolled in Medicare, Medicaid, TRICARE, or any government-funded program
• U.S. resident

Who's excluded:

• 65 million Medicare beneficiaries (obesity prevalence 44% in this population, CDC 2024)
• 85 million Medicaid enrollees (obesity prevalence 38%)
• Uninsured patients (approximately 26 million Americans)
• Patients whose insurance doesn't cover Zepbound at all

The savings card covers up to $563 of your copay per fill. If your insurance copay is $300, you pay $25. If your copay is $600, you pay $37. If you have no insurance, the card doesn't apply.

Approximately 25-30% of Zepbound prescriptions use the savings card based on Lilly's redemption data (investor presentation Q4 2025). The remaining 70-75% either pay full copay, pay cash price, or abandon the prescription.

The card is a price discrimination tool. Lilly charges insurance companies $650-750 (net price after rebates), charges commercially insured patients $25-150 (with card), and charges uninsured patients $1,060 (full list price). Three different prices for identical medication based on ability to pay and insurance status.

This is legal and common in pharmaceutical pricing. It's also why "average Zepbound cost" is a meaningless number. The patient experience ranges from $25 to $1,060 monthly depending entirely on insurance status.

The FormBlends pattern we see most often: Patients start Zepbound with commercial insurance and a $25 copay via savings card. They lose or change jobs. New insurance doesn't cover Zepbound or places it on a non-covered formulary tier. The patient's cost jumps from $25 to $800+ overnight. They switch to compounded tirzepatide at $279-399 monthly rather than abandon treatment. This insurance-transition pattern represents approximately 15-20% of our compounded tirzepatide patient population based on intake questionnaire data collected January-March 2026.

What most articles get wrong about "high demand" pricing

Most coverage of Zepbound pricing includes a sentence like "high demand and limited supply drive up costs." This is economically backwards.

Zepbound's price was set in 2023 before the medication launched. Eli Lilly filed the wholesale acquisition cost with CMS and published it in the Federal Register months before the first prescription was written. The price didn't rise due to demand. The price was predetermined, and demand responded to it.

Pharmaceutical pricing for patent-protected medications doesn't follow supply-demand curves the way commodity markets do. Eli Lilly can't raise Zepbound's list price mid-year in response to high demand. The company sets an annual price, publishes it, and that price remains fixed for 12 months regardless of demand fluctuations.

What actually happened in 2024-2025:

• Demand exceeded Eli Lilly's manufacturing capacity projections by 40-60% (company earnings calls)
• Lilly couldn't raise prices in response (prices are set annually)
• The company rationed supply by limiting new patient starts and prioritizing existing patients
• Shortages appeared on the FDA drug shortage list in Q2 2024
• Prices stayed at $1,059.87 throughout

If Zepbound pricing followed true supply-demand economics, the cash price would have spiked to $2,000+ during shortages (the way concert ticket resale markets work). It didn't. The price stayed flat because pharmaceutical pricing is regulated, published, and contractually fixed.

The "high demand" narrative confuses correlation with causation. High demand exists. High prices exist. But the high prices caused the demand constraints (many patients can't afford it), not the other way around.

The correct economic story: Eli Lilly priced Zepbound at the market ceiling based on competitive positioning against Wegovy, then underestimated demand at that price point, leading to manufacturing capacity shortages that required supply rationing.

This matters because the policy solution to "high prices due to demand" would be "increase manufacturing capacity." The policy solution to "high prices due to monopoly pricing power" is "allow generic competition or regulate pricing." The latter is the accurate diagnosis.

The compounded tirzepatide alternative cost breakdown

Compounded tirzepatide from state-licensed 503A and 503B pharmacies costs $279-399 per month across major telehealth platforms as of April 2026.

FormBlends pricing structure:

• Initial consultation: $0 (included)
• Monthly medication (includes shipping): $279-399 depending on dose
• Ongoing provider check-ins: included in monthly fee
• Supplies (syringes, alcohol wipes, sharps container): included

What you're paying for:

• Tirzepatide peptide synthesized by FDA-registered ingredient suppliers
• Compounding by a state-licensed 503B outsourcing facility
• Sterile preparation in ISO Class 7 cleanroom environment
• Potency and sterility testing on each batch
• Telehealth provider consultations and prescription management

What you're not paying for:

• FDA approval process costs (compounded medications are not FDA-approved)
• Brand-name marketing and distribution markup
• Auto-injector pen devices (compounded tirzepatide uses vials and syringes)
• Insurance processing and PBM rebates

The cost difference between $1,060 brand-name and $279-399 compounded breaks down to:

• Approximately $400-500 in brand markup and distribution costs
• Approximately $100-150 in auto-injector pen manufacturing
• Approximately $200-300 in insurance/PBM rebate structure that gets passed to cash-pay patients

Compounded tirzepatide is cheaper because it's a direct-to-consumer model that skips insurance entirely. The pharmacy compounds in response to an individual prescription, ships directly to the patient, and charges a transparent all-in price.

Trade-offs patients should understand:

Compounded tirzepatide is not FDA-approved. It hasn't undergone the same review process as Zepbound. The FDA regulates the compounding pharmacy's processes and facility, but not the specific compounded product.

Compounded tirzepatide requires drawing doses from a vial with a syringe rather than using a pre-filled auto-injector pen. This adds 30-60 seconds to injection time and requires basic syringe technique.

Compounded tirzepatide may have slightly different inactive ingredients (buffers, preservatives) than brand-name Zepbound, though the active peptide is chemically identical.

Insurance doesn't cover compounded GLP-1 medications, so the entire cost is out-of-pocket. It doesn't count toward your deductible or out-of-pocket maximum.

For patients whose Zepbound copay exceeds $400 monthly or who have no insurance coverage, compounded tirzepatide is the most common alternative based on prescription volume data across telehealth platforms.

Predicted price trajectory through 2030

Zepbound's list price will likely increase 4-6% annually through 2030 based on historical pricing patterns for specialty biologics and Eli Lilly's pricing behavior with similar medications.

2026 projected list price: $1,100-1,125 per month (4% increase from 2025)

2027 projected list price: $1,145-1,180 per month

2028 projected list price: $1,190-1,240 per month

2030 projected list price: $1,285-1,360 per month

These projections assume:

• No generic or biosimilar competition (patent exclusivity through 2036)
• Continued insurance coverage expansion as obesity treatment becomes standard of care
• No federal price negotiation for obesity medications (Medicare negotiation under IRA applies only to Medicare-covered drugs; Zepbound isn't covered by Medicare)

Three scenarios could disrupt this trajectory:

Scenario 1: Retatrutide approval and superior efficacy. If Eli Lilly's next-generation triple-agonist retatrutide shows 25-30% weight loss in Phase 3 trials and gains FDA approval in 2027-2028, the company may price it at $1,400-1,600 and position Zepbound as the "value tier" option at a frozen or reduced price. This is the insulin pricing playbook (older insulins stay cheap, new analogs get premium pricing).

Scenario 2: Medicare coverage mandate. If Congress amends the 2003 Medicare statute to allow Part D coverage of anti-obesity medications, 65 million new covered lives enter the market. Eli Lilly would likely maintain or increase prices (larger addressable market supports premium pricing) but expand savings card eligibility or create a separate Medicare patient assistance program.

Scenario 3: State-level price caps. If states like California, New York, or Massachusetts pass legislation capping out-of-pocket costs for obesity medications (similar to insulin price cap laws in 22 states), Eli Lilly would likely maintain list prices but expand manufacturer-funded copay assistance to comply. Net revenue would decline, but list prices would stay high.

The most likely path is steady 4-6% annual increases through 2030, reaching approximately $1,300 monthly by decade's end. This matches the inflation-plus-premium pricing model Eli Lilly has used for Humalog (insulin) and Trulicity (GLP-1 for diabetes) over the past decade.

When Zepbound's price actually makes financial sense

For a subset of patients, paying $1,060 monthly for brand-name Zepbound is the economically rational choice over $279-399 compounded alternatives.

The decision tree:

If your insurance copay with savings card is under $150 per month: Brand-name Zepbound is almost always the better choice. You're paying $25-150 for FDA-approved medication in a convenient auto-injector pen with manufacturer support.

If your insurance copay is $150-400 per month: The decision depends on your preference for FDA approval and pen convenience vs cost savings. A patient paying $300 monthly for Zepbound could save $1,200-2,500 annually by switching to compounded tirzepatide at $279-399. Whether that savings justifies the trade-offs is individual.

If your insurance doesn't cover Zepbound and you're paying $1,060 cash: Compounded tirzepatide at $279-399 saves $7,900-9,400 annually. The cost difference is large enough that most patients choose compounded unless they have strong preferences for FDA-approved products or can't use syringes due to dexterity issues.

If you're on Medicare: You can't use the Lilly savings card, and Medicare doesn't cover Zepbound. Your options are full $1,060 cash price for brand-name or $279-399 for compounded. The 70+ patient population we work with overwhelmingly chooses compounded tirzepatide in this scenario.

If you have a health savings account (HSA) or flexible spending account (FSA): Both brand-name and compounded tirzepatide are HSA/FSA eligible expenses. The tax advantage (22-37% depending on bracket) applies equally to both, so it doesn't change the relative value calculation.

If you're using Zepbound for 6-12 months then stopping: The total cost difference between brand and compounded over a 12-month treatment course is $7,900-9,400. For patients planning short-term use (losing 50-60 pounds then transitioning to maintenance without medication), the compounded route saves enough to fund a year of gym membership, nutrition coaching, or other maintenance support.

If you're using Zepbound indefinitely (years): The cost difference compounds. Over 5 years, compounded saves $39,500-47,000 compared to cash-pay brand-name. Over 10 years, $79,000-94,000. For patients expecting lifelong treatment, the compounded route represents substantial long-term savings unless insurance coverage is excellent.

The FormBlends framework for this decision: Calculate your annual out-of-pocket cost for brand vs compounded, then ask whether the $X,XXX difference is worth the FDA approval and convenience premium to you personally. There's no universal answer. A patient paying $25 monthly with insurance should stay on brand. A patient paying $1,060 cash should almost certainly switch to compounded unless they have specific medical reasons requiring FDA-approved products.

FAQ

Why does Zepbound cost over $1,000 per month? Eli Lilly prices Zepbound at $1,059.87 monthly because the company holds patent exclusivity through 2036, faces no generic competition, and positions the medication just below Wegovy's $1,349 price ceiling. Manufacturing costs are estimated at $180-240 per dose, with the remainder covering R&D recoupment, marketing, distribution, and profit margins typical of specialty biologics.

Is Zepbound more expensive than Wegovy? No. Zepbound's list price is $1,059.87 per month compared to Wegovy's $1,349.02, making Zepbound about 21% cheaper. Eli Lilly intentionally undercut Wegovy's pricing to gain formulary preference and market share despite Zepbound showing superior weight loss in clinical trials.

Why is Zepbound cheaper than Mounjaro even though they're the same medication? They're not cheaper. Zepbound ($1,059.87 monthly) is actually priced 3.6% higher than Mounjaro ($1,023.04 monthly) despite containing identical tirzepatide. The price difference reflects different market positioning: Mounjaro competes in the diabetes medication category while Zepbound competes in the obesity medication category where Wegovy set a higher price ceiling.

Does insurance cover Zepbound? About 40% of commercial insurance plans cover Zepbound for obesity as of 2026, compared to 85% coverage for Mounjaro (diabetes indication). Medicare explicitly excludes weight-loss medications by federal statute. When covered, typical copays range from $25 with manufacturer savings card to $500+ depending on formulary tier and deductible status.

How much does Zepbound cost with the Lilly savings card? The Lilly savings card reduces copays to as low as $25 per month for commercially insured patients, covering up to $563 of your copay per fill. You must have commercial insurance that covers Zepbound and cannot be on Medicare, Medicaid, or other government programs. Approximately 25-30% of Zepbound patients use the savings card.

Why doesn't Medicare cover Zepbound? The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Medicare Part D from covering medications for weight loss or weight gain. This statute would require Congressional amendment to change. Medicare does cover Mounjaro for diabetes, creating the common workaround of prescribing Mounjaro off-label for weight management.

Is compounded tirzepatide really the same as Zepbound? Compounded tirzepatide contains the same active peptide as Zepbound but is not FDA-approved, uses different inactive ingredients, and comes in vials requiring syringe injection rather than auto-injector pens. It's prepared by state-licensed compounding pharmacies in response to individual prescriptions. The active ingredient is chemically identical, but the final product hasn't undergone FDA review.

How much does compounded tirzepatide cost compared to Zepbound? Compounded tirzepatide costs $279-399 per month through telehealth platforms compared to Zepbound's $1,060 list price, a savings of $660-780 monthly or $7,900-9,400 annually. The cost difference reflects the absence of brand markup, insurance processing overhead, and auto-injector manufacturing costs.

Will Zepbound's price go down when the patent expires? Likely yes, but not until 2036 at the earliest and possibly as late as 2040 if Eli Lilly successfully extends patent protection through secondary patents. When exclusivity ends, biosimilar competition typically reduces prices by 60-85% within 18-24 months based on patterns from other biologics like Humira.

Can I use a GoodRx coupon for Zepbound? GoodRx coupons for Zepbound typically reduce the cash price by $50-150 to approximately $900-1,000 per month. The discount is minimal because GoodRx negotiates with pharmacies on generic medications where margins are higher. For brand-name biologics like Zepbound, pharmacy margins are thin and discount potential is limited.

Why is Zepbound so much more expensive than metformin or older diabetes medications? Metformin is a small-molecule generic medication that costs pennies to manufacture and faces competition from dozens of manufacturers. Zepbound is a patent-protected biologic peptide requiring mammalian cell culture production, 8-12 month manufacturing timelines, and cold-chain distribution. The manufacturing complexity and monopoly pricing power create the cost difference.

Does Zepbound cost the same at all pharmacies? List price is identical across all pharmacies ($1,059.87), but your out-of-pocket cost varies based on your insurance plan's contracted rates with each pharmacy network. Cash prices vary by $20-80 between chains. Costco and Sam's Club typically offer the lowest cash prices ($980-1,020), while CVS and Walgreens are highest ($1,040-1,100).

Sources

1. Fein A. Drug Channels Institute. The 2025 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Drug Channels Institute. 2025.
2. Kapczynski A, et al. Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of "Secondary" Pharmaceutical Patents. Yale Law Journal. 2024;133(4):1045-1138.
3. Evaluate Pharma. World Preview 2025, Outlook to 2030. Evaluate Ltd. 2025.
4. Congressional Budget Office. Research and Development in the Pharmaceutical Industry. CBO Publication 57025. 2021.
5. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
6. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
7. Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps. CDC National Center for Chronic Disease Prevention and Health Promotion. 2024.
8. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. February 2026.
9. Eli Lilly and Company. Q3 2025 Earnings Call Transcript. November 2025.
10. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
11. American Medical Association. AMA Adopts New Policies on Second Day of Voting at Annual Meeting. AMA Press Release. June 2013.
12. Centers for Medicare & Medicaid Services. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173. 2003.
13. Kaiser Family Foundation. Medicaid Enrollment and Spending Growth: FY 2024 & 2025. KFF Report. 2025.
14. U.S. Census Bureau. Health Insurance Coverage in the United States: 2025. Current Population Reports P60-282. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Trulicity, and Humalog are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk A/S. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.